Prioritizing Gene Cascading Paths to Model Colorectal Cancer Through Engineered Organoids

Introduction

The well-known adenoma–carcinoma sequence model described a basic carcinogenesis mechanism of colorectal cancer (CRC) (Vogelstein and Kinzler, 2004; Brenner et al., 2014). The sequential genetic alterations of APC, KRAS, SMAD4, and TP53 could recapitulate the key features in transition from normal to adenoma and to initiation and progression of CRC, which promoted the understanding of pathogenesis in CRCs (Powell et al., 1992; Drost et al., 2015; Chen et al., 2016). Mutations on these genes could deregulate driver pathways to confer selective growth advantages and further to drive colorectal carcinogenesis. Tumor suppressor gene APC acted as an antagonist of the WNT signaling pathway. The inactivating mutations of APC could initiate a benign adenoma by activating the WNT pathway (Powell et al., 1992; Roper et al., 2017; Takeda et al., 2019), which was proved by the upregulation of β-catenin driven by APC mutations (Matano et al., 2015). The follow genetic alterations in KRAS, SMAD4, and TP53 further promoted the transition of adenoma to CRC by activating EGFR, P53 and TGF-β pathways (Drost et al., 2015; Chen et al., 2016). KRAS was reported to play driver roles during the progression from early to intermediate adenoma stages (Takeda et al., 2019). The activating mutations in KRAS could activate EGF signaling. The SMAD4 and TP53 mutations promoted the transition from adenoma to adenocarcinoma stages (Fearon and Vogelstein, 1990). SMAD mutations reduced the SMAD protein and inhibited TGF-β signaling pathway. The mutation in TP53 could overexpressed a truncated TP53 protein which made TP53 lose tumor suppressor roles (Tang et al., 2019). However, due to the high heterogeneity of genetic alterations across CRC population, it was inefficient for these driver mutations to characterize the molecular mechanism of broad CRC patients. Prioritizing different gene cascading paths for directing sequential introduction of key mutations were the pressing problem.

Organoids, as an in vitro 3D models, could closely recapitulate genetic spectra of original tissues (Morizane et al., 2015). For example, tumor organoids closely recapitulated the molecular spectra in CRC (van de Wetering et al., 2015). Introducing key mutations into organoids other than cells could provide better manners to examine the influence of driver genes during cancer carcinogenesis. Directly targeting modification of cancer genes could produce cancer cells from the mouse primary cells or in vivo tissue (Ran et al., 2013; Heckl et al., 2014; Platt et al., 2014; Sánchez-Rivera et al., 2014; Xue et al., 2014). Driver gene-targeted engineered organoids could grow in hostile medium while normal intestinal organoids ceased proliferation. We summarized the recent studies modeling CRC using intestinal organoids with introducing driver mutations in APC, SMAD4, KRAS, TP53, and PIK3CA (Table S1) (Cooks et al., 2013; Onuma et al., 2013; Drost et al., 2015; Matano et al., 2015; Chen et al., 2016; Nakayama et al., 2017; O'Rourke et al., 2017; Riemer et al., 2017; van Lidth de Jeude et al., 2017). APC mutations activated WNT signaling and promoted the growth of intestinal organoids in medium lacking WNT signaling (Matano et al., 2015). Intestinal organoids with APC mutations developed into benign tumors after transplantation (O'Rourke et al., 2017). SMAD4 mutation-targeted organoids could grew in condition without inhibitor of TGF-β receptor signaling that was essential for sustaining the growth of normal intestinal cells (Matano et al., 2015). Engineered organoids expressing KRAS mutations could expand in the condition withdrawing EGFR signaling (Matano et al., 2015). TP53 mutations induced prolongation of activation of NF-kappaB signaling, and promoted inflammation-associated colorectal cancer (Cooks et al., 2013). TP53 mutation-targeted organoids could recover in the condition of activation of TP53 signaling pathway which can induce cell cycle arrest and apoptosis (Matano et al., 2015). Oncogenic PIK3CA could regulate cell motility though AKT, and PIK3CA mutations played key roles in reprograming glutamine metabolism in colorectal cancers (Hao et al., 2016). PIK3CA mutations could induce cell attachment and motility under cooperation of CTNNB1 (Riemer et al., 2017). Oncogenic PIK3CA could regulate cell motility though AKT, and PIK3CA mutations played key roles in reprograming glutamine metabolism in colorectal cancers (Hao et al., 2016). Sequential introducing different combinations of these driver mutations could delineate the progression from normal epithelium to adenoma and carcinoma. Engineered organoids with APC and KRAS mutations grew into lager dysplasia without invasive features (Takeda et al., 2019), and further formed invasive submucosal tumor under condition of inhibited TGF-β signaling pathway (Chen et al., 2016; Takeda et al., 2019). These studies implied that engineered organoids with sequential introducing driver mutations could provide new clues to exploring developmental mechanisms of cancers. However, whether these engineered organoids were sufficient to capture broad cancer behaviors were still a challenge.

The transformation of normal cells to tumor cells was the dynamic dysregulated procession of cellular homeostasis, which was the requirement for the organism function normally (Rosenfeldt et al., 2013). The activity of biological functions could reflect the extent of homeostasis. Many functional activity-based methods were proposed to reveal the disease mechanisms (Lee et al., 2008; Gatza et al., 2010; Drier et al., 2013). The patterns of functional activity made tumor disease classification more precise and built subtype characterizations (Lee et al., 2008; Gatza et al., 2010). The function dysregulated scores characterized the deregulated extent of functions in individual samples (Drier et al., 2013). Measuring the difference of function activity among different cancer stages could help characterizing the dynamic progression of CRC.

In this work, from the single-mutant to quintuple-mutant engineered organoids, we dynamically characterized the function activities of hallmark signatures and measured the biological gaps between the engineered organoids and the CRC samples. An integrative strategy was designed to prioritize the gene cascading paths which could help us to understand the carcinogenesis mechanism of broad CRC patients with different profile of genetic alterations (Figure 1).

FIGURE 1

Figure 1. The overview of the integrative strategy for prioritizing gene cascading path.

Materials and Methods

Data Collection and Processing

Gene Expression Profiles and Mutation Profiles of Colorectal Cancer

We downloaded the gene expression profiles (GSE57965) of adenoma and engineered organoids (Table S3), which contained five adenoma samples with APC mutation (A-organoid), 1 adenoma sample with genetic modification of SMAD4 deletion (AS-organoid), 1 adenoma sample of genetic modification of knocking in KRAS^G12V (AK-organoid), 2 engineered human colon organoids carrying four gene mutations (APC, KRAS^G12V, SMAD4, and TP53, AKST-organoids) and 1 engineered human colon organoids carrying five gene mutations (APC, KRAS^G12V, SMAD4, TP53, and PIK3CA^E545K, AKSTP-organoid) (Matano et al., 2015). The gene expression profile with 20,014 genes were obtained after removing probes corresponding to multiple genes and averaging the expression level of multiple probes of each gene.

We also downloaded the somatic mutation data (level 2) and gene expression profiles (RNA-seq) of colorectal cancer from the cancer genome atlas (TCGA). We extracted a mutation profiles which contained the samples with mutations in at least one of five genes (including APC, SMAD4, TP53, KRAS, and PIK3CA) and removed mutation types of silent, intron and 5'UTR. Finally, we obtained 103 samples with both gene expression profile and mutation profile (Table S3), in which 54 samples only with APC mutation, 40 samples only with mutations in both APC and KRAS, 3 samples with mutations only in both APC and SMAD4, 1 sample with mutations only in four genes (APC, KRAS, SMAD4, and TP53), and five samples with mutations of all of five genes.

KEGG Pathways and HPRD Protein Interaction Network

We downloaded the KGMLs of 222 human pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa and Goto, 2000). To get the topological information of these pathways, we got the corresponding undirected graphs of pathways and the degrees of genes in these pathways using the R package iSubpathwayMiner (Li et al., 2009). Only the pathways in which genes were connected with each other were kept. Finally, we obtained 186 pathways as the functions to characterize the biological gaps between organoids and cancer samples.

The protein interaction network was obtained from the Human Protein Reference Database (HPRD, version 9) (Keshava Prasad et al., 2009), which contained 9,617 genes and 39,240 interactions among these genes.

Methods

We proposed an integrative strategy to prioritize the gene cascading path for directing CRISPR-Cas9 to construct colorectal cancer organoids (Figure 1).

Integrating the Gene Expression Profiles From GEO and TCGA Using Rank-Based Scores

To joint analysis of expression profiles from GEO and TCGA, we used the Rank-based scores (Amar et al., 2015) to normalize the expression profiles of engineered organoids and CRC samples. 18,071 common genes were detected by both GEO and TCGA. For each sample s, the expression values of 18,071 genes were sorted in the decreasing order. Rank of highest expressed gene was 1 and that of lowest one was 18,071. The rank i of gene g was transformed into rank-based score: $W_s(g_i)=i{e}^{-\frac{i}{18071}}$. The rank-based scores of genes in the samples were used to joint analysis.

Identifying Dysregulated Functions in Biological Gaps Between Engineered Organoids and Corresponding CRC Samples

To investigate the potential driver capability of driver mutations, we characterized the biological distance from engineered organoids to CRC samples by identifying the dysregulated functions.

Functional Activity

Functional activity could measure the active status of biological functions in a specific sample (Bild et al., 2006). For each sample, we calculated functional activities of 186 functions using a Normalized Centroid shift method (Yang et al., 2012). For each function j, we classified the 18,071 genes (G) into two classes: genes within the function j (G_funj) and the other genes (G/G_funj). We calculated the average rank-based scores NC_Gfunj and NC_G/Gfunj, and then the activity score of function j (FAS_funj) was calculated as the difference between NC_Gfunjand NC_G/Gfunj.

$\begin{array}{l}N{C}_{G_{fu{n}_j}}=\frac{{\displaystyle \sum _{g_i\in G_{fu{n}_j}}}{W}_s(g_i)}{\left|G_{fu{n}_j}\right|}\\ N{C}_{G/G_{fu{n}_j}}=\frac{{\displaystyle \sum _{g_i\in G\cap g_i\notin G_{fu{n}_j}}}{W}_s(g_i)}{|G/G_{fu{n}_j}|}\\ FA{S}_{fu{n}_j}=N{C}_{G_{fu{n}_j}}-N{C}_{G/G_{fu{n}_j}}\end{array}$

Identifying Dysregulated Functions With Significant Activity Difference Between the Engineered Organoids and CRC Samples

To measure the biological distance from engineered organoids (S) and corresponding CRC samples (T), we compared the activities of 186 functions between S and T. For each type of mutation combination, we calculated the average functional activities of each function, $FA{S}_{fu{n}_j}^s$ and $FA{S}_{fu{n}_j}^T$, for S and T. The $\text{DFA}{\text{S}}_{fu{n}_j}=|FA{S}_{fu{n}_j}^s-FA{S}_{fu{n}_j}^T|$ measure the activity difference. To determine the significance of activity difference and identify dysregulated functions, the gene expression profiles of S and T were permuted 1,000 times, respectively. We re-calculated 1,000 random DFAS as described above. The significance P was calculated as the frequency in which random DFAS was larger than real DFAS. We identified the dysregulated functions as those at FDR = 0.01.

Inferring Subsequent Key Genes During the Progression of CRC

The known driver mutations were inefficient to capture cancer behaviors and to broadly explain cancer mechanisms. Exploring the subsequent key genes of known driver mutations can improve the understanding of modeling CRC. We utilized Random walk with restart (RWR) (Köhler et al., 2008) to infer subsequent key genes during the progression of CRC for five types of organoids.

For each dysregulated function k obtained from a specific organoid, we reconstructed a biological network based on the pathway structure. We calculated the degrees of genes in the dysregulated function and selected the top 10% genes with the highest degrees as the seed genes which were the input of random walk. The seed genes were sowed into the protein interaction network. The information flow can restart from the seed genes with probability r in RWR (Köhler et al., 2008):

$\begin{array}{l}{P}_{t+1}=(1-r)W{P}_t+r{P}_0\end{array}$

where r was set to 0.7; $P_0$was the initial probabilities of genes, in which the probabilities of seed genes was $\raisebox{1ex}{$1$}\!\left/ \!\raisebox{-1ex}{$n$}\right.$ (n was the number of seed nodes) and others 0; $P_t$were the probabilities of genes at the t_th steps; W was the normalized transfer matrix of the protein interaction network; the random walk process reached the steady-state when the maximum difference between $P_{t+1}$and $P_t$was <10⁻⁸. The $P_{t+1}$ characterized the functional similarity of genes with seed genes. We randomly selected 1,000 sets of pseudo seed genes with the same size and re-performed random walk. For each gene j in the protein interaction network, the significance $P_j^k$ was calculated as the frequency in which random functional similarity was larger than real one. Finally, we combined the significance ($P_j^k$) of gene j calculated from all dysfunctional functions (k = 1……K) into a statistic X which follow the χ² (2K) distribution:

$\begin{array}{l}{\chi }^2=-2{\displaystyle \sum _{k=1}^K}\text{ln }{P}_j^k\end{array}$

Where the K was the number of dysfunctional functions. The P(X ≥ χ²|X ~ χ²(2K)) represented the significance of genes. We considered genes with FDR ≤ 0.05 as subsequent key genes.

Prioritizing Gene Cascading Paths to Recapture the Adenoma-Carcinoma Sequence of CRC

High tumor heterogeneity of genetic alterations in CRC made the well-known adenoma-carcinoma sequence explain a part of CRC patients, additional alternative gene paths were needed to interpret the development progression of more extensive CRC patients. Different patients with similar phenotype had different combinations of genetic alterations that tended to participate in same or similar functions. To prioritize gene cascading paths for each type of organoid, firstly, we calculated the functional coherence among the five known genes and the subsequent key genes (Wang et al., 2007), and constructed the functional consistency network at the threshold of 0.4. Then, a sparse functional consistency network was constructed by selecting two neighbors with highest functional consistency for each gene. Finally, using the well-known adenoma-carcinoma sequence model as the template, each gene cascading path was identified by starting from the mutant genes in the organoids and ending at the potential key gene showing the maximum shortest distance with mutant genes.

Stepwise Comparison of Five Types of Organoids in the Activities of Hallmark Signatures

We compared the activities of 50 hallmark signatures among five types of organoids (including A-organoid, AS-organoid, AK-organoid, AKST-organoid, and AKSTP-organoid) in a stepwise way. For a pair of organoids, we identified the significant activation/inactivation of hallmark signatures in the organoid with more mutations by comparing with the other. The activities of 50 hallmark signatures were estimated using gene set enrichment analysis, and the activity differences between the pair of organoids were calculated. To measure the significance of activity differences, we permutated the transcriptomes of the pair of organoids 1,000 times, and recalculated 1,000 random activity differences of hallmark signatures. The significance of activation was calculated as the frequency in which random activity differences was larger than real one. And the significance of inactivation was calculated as the frequency in which random activity differences was smaller than real one. We identified the significant activation/inactivation of hallmark signatures at FDR ≤ 0.05.

Results

The Combination Mutation Patterns in Five Driver Genes Across CRC Populations

The mutations of five genes (including APC, KRAS, SMAD4, TP53, and PIK3CA) were reported to play driver roles in CRC progression. Five CRC populations in the cbioPortal were collected to investigate the mutation distributions of the five driver genes (Cerami et al., 2012; Gao et al., 2013). We found that these five genes showed high mutation frequencies ranging from 77 to 100% (Figure 2A). As a “gatekeeper” gene, APC mutations were extremely pervasive across CRC populations. Especially, the mutation frequency of APC reached up to 91% in MSKCC study (Figure S1 and Table S2). The mutation frequencies of TP53 were 82, 53, 55, 56, and 43% across five CRC populations; 55, 42, 44, 51, and 28% for KRAS; 20, 20, 15, 31, and 21% for SMAD4; and 12, 14, 15, 24, and 10% for PIK3CA. The high frequencies of these five driver genes confirmed their core roles in the progression of CRC. Interestingly, only 0.72, 0.94, 0.45, 0% (0/72), 0% samples harbored the mutations of all five genes across the five CRC populations (Figure 2B). CRC samples harboring mutations in four genes only occupied 16.7, 5.7, 5.5, 8.3, and 3.9%, respectively. Most CRC samples (74.6, 65.1, 63.6, 58.3, and 54.1%) carried mutations of two or three genes. And the most common combination of mutations was observed between APC and TP53. These results further showed CRC was a highly heterogeneous disease from genomic perspective. Different CRC patients harbored different combinations of genetic alterations. The mutation frequency of single driver gene was high while the co-occurrence frequency of the five driver genes was very low. These phenomenon implied that although the mutations of the five driver genes could explain the CRC pathogenesis well, which could only explain the progressive mechanism for a fraction of CRC patients, but the molecular pathogenesis of major patients remains unclear. There existed other gene paths or mutation combinations to drive CRC evolution.

FIGURE 2

Figure 2. The mutation distributions of five driver genes in the five CRC populations. (A) The mutation frequencies of the five genes across five CRC populations. (B) Combination patterns of mutations in the five genes across CRC populations.

Functionally Characterizing Engineered Organoids Carrying Various Combinations of Driver Mutations

We collected the transcriptomes of five types of engineered organoids which expressed mutations of different combinations of the five genes from GSE57965. For each type of engineered organoid, we calculated the activities of 50 hallmark signatures from MSigDB and identified the hallmark signatures with significant activation or inactivation using gene set enrichment analysis (Subramanian et al., 2005; Liberzon et al., 2015). In A-organoid, epithelial mesenchymal transition was the most significantly activated development signature (Figure S2A, P < 0.001). The immune signatures [IL6- JAK-STAT3 signaling (P = 0.0012) and inflammatory response (P = 0.001)] also showed significant activation. Five of six proliferation signatures showed significant activation in AK-organoid, which contained G2M checkpoint (P < 0.001) and E2F targets (P < 0.001). In AKST- and AKSTP-organoids, the hypoxia and glycolysis signature showed significant activation. Notably, none of 50 hallmark signatures showed significant inactivation in AKSTP-organoid (Figure S2B), indicating AKSTP-organoid exhibited more cancer hallmarks. These results suggested that the introduction of the five driver genes in intestinal organoids could induce the activation of hallmark signatures.

Dynamically Analyzing CRC Progression From A- to AKSTP-Organoids

To further characterize the dynamic activities of hallmark signatures during sequential introduction of multiple driver mutations, we compared the activities of hallmark signatures between the five types of organoids. Compared with A-organoids, the other four types of organoids showed consistent activation of proliferation signatures containing G2M checkpoint and E2F targets (Figure 3A). Further, compared with AK- and AS-organoids, the AKST- and AKSTP-organoids consistently activated the hypoxia and glycolysis signature (Figures 3B,C). Compared with AKST-organoid, the AKSTP-organoid continued to enhance activation of proliferation signatures (MYC targets and P53 pathway) and immune signatures (Figure 3D). These dynamic analyses suggested that sequential introduction of these driver mutations gradually drove the activation of distinct hallmark signatures, and conferred the selective advantages to engineered organoids.

FIGURE 3

Figure 3. Dynamic activity analysis of 50 hallmark signatures from A-organoid (A) to AKSTP-organoid (AKSTP). (A) The significant activation (red) or inactivation (blue) of 50 hallmark signatures in AS-organoid (AS), AK-organoid (AK), AKST-organoid (AKST), and AKSTP-organoid (AKSTP) by comparing with A-organoid (A). (B) The significant activation (red) or inactivation (blue) of 50 hallmark signatures in AKST-organoid and AKSTP-organoid by comparing with AS-organoid. (C) The significant activation (red) or inactivation (blue) of 50 hallmark signatures in AKST-organoid and AKSTP-organoid by comparing with AK-organoid. (D) The significant activation (red) or inactivation (blue) of 50 hallmark signatures in AKSTP-organoid by comparing with AKST-organoid.

Functionally Characterizing Combined Effects of the Five Driver Mutations Using TCGA CRC Patients

We collected CRC samples with both expression and mutation profiles from TCGA. The mutations of the driver genes could influence gene expression levels of driver genes (P = 0.021 for APC, P = 0.0174 for SMAD4, P = 2.7e−5 for TP53, P = 0.0013 for KRAS, and P = 0.0183 for PIK3CA, Figure S3). According to the mutation status of the five driver genes, the 103 CRC samples were grouped into five groups (Table S3). To evaluate whether CRC samples with different combinations of driver mutations showed differential activities of hallmark signatures, we calculated the activities of hallmark signatures using single-sample GSEA for each CRC sample (Hänzelmann et al., 2013). For each group, average activities of hallmark signatures were calculated. We found that these five groups showed similar activated patterns (Figure 4A). The correlation coefficients of average activities ranged from 0.973 to 0.999 (Figure 4B). To further investigate whether the similar activated patterns also exited in all CRC samples, the correlation coefficients among all CRC samples were calculated. We found that all CRC samples still exhibited highly consistent correlation of hallmark signature activities in spite of different combinations of genetic alterations (Figure 4C). The results suggested that there existed additional driver genetic alterations contributing to development mechanism of broad CRC patients.

FIGURE 4

Figure 4. Highly consistent correlations of 50 hallmark signature activities across CRC samples with different combinations of mutations in five genes. (A) The average activity scores of hallmark signatures in five different groups of CRC samples. (B) The correlations of hallmark signature activities across five groups. (C) The correlations of hallmark signature activities across CRC samples.

Substantial Biological Gaps Between Engineered Organoids and Colorectal Cancer Tissues

We used the rank-based scores to integrate the expression profiles of engineered organoids and CRC samples. The result of principal components analysis showed that the expression pattern could distinguish the five types of organoids from TCGA CRC samples (Figure S4). To characterize the biological distance from the engineered organoids to CRC, we identified the dysregulated functions with significant activity difference between engineered organoids and their corresponding CRC samples at FDR = 0.01 against 1,000 permutations (Table S4).

For the A-organoids, we found that 65 of 186 functions showed no significant difference of functional activities by contrast to CRC samples, two of which APC participated in directly. For example, APC participated in the Wnt signaling pathway directly. In the A-organoids, the WNT pathway showed similar functional activity with the CRC samples with APC mutation (P = 0.015, Figure S5A). However, the Wnt signaling pathway showed significant activity difference (P = 0.008, Table S4) by comparing normal and CRC samples. These results suggested that APC mutation contributed the activation of Wnt signaling pathway, which was consistent with previous studies (Drost et al., 2015; Matano et al., 2015). Meanwhile, there were 121 dysregulated functions with significant activity difference. The MAPK signaling pathway showed significant activity difference between A-organoids and CRC samples (P < 0.001, Figure S5B). The number of functions showing similar activities between AK-organoids and corresponding CRC samples were up to 128, and the number of dysregulated functions decreased to 58. The RAS and MAPK signaling pathway showed similar activity between AK-organoids and CRC samples (P = 0.11 and P = 0.33, Figures S5C,D), suggesting the combination of APC and KRAS mutations enabled the activity of RAS and MAPK signaling pathway to reach the physiological state of CRCs. We also compared the function activity between AS-organoid, AKST-organoids, AKSTP-organoids and their corresponding CRC samples. We found that the number of functions with similar activity increased and the number of dysregulated functions decreased along with the number of genes mutations (Figure 5A and Table S4). These results gave a clue that combinations of multiple drive mutations approximated the organoids to CRC by activating or inactivating the activities of functions.

FIGURE 5

Figure 5. The dysregulated functions identified in the gaps between five types of organoids and CRC samples. (A) The number of dysregulated functions identified five types of organoids. (B) The binary heatmap of dysregulated functions across five types of organoids. (1 represents dysregulated functions, and 0 represents not).

To characterize the step-by-step progression of CRCs from organoids engineered by introducing mutations, we compared the activity difference of 186 functions from five types of organoids. Firstly, we focused on the five functions including Wnt signaling pathway, RAS-MAPK signaling pathway, TGF-β signaling pathway, TP53 signaling pathway and PI3K signaling pathway, which were targeted by APC, SMAD4, KRAS, TP53, and PIK3CA, respectively. By comparing the normal and CRC samples, we found four functions including Wnt, RAS-MAPK, TP53 and PI3K signaling pathway showed significant differential activity(P = 0.008, P < 0.001, P < 0.001, and P = 0.003, Table S4). By introducing the mutations of corresponding genes, we found the significance of activity difference of four functions disappeared gradually (Table S5, FDR = 0.01). With the increasing number of mutated genes, the activity difference of these functions between organoids and CRCs tended to random state, suggesting the driver progression of key genes during carcinogenesis.

To further investigate the dynamic progression integrally, we clustered the organoids and the 186 functions based on the significance status of dysregulated functions. We found that A- and AS-organoids were a class, and AK-, AKST-, and AKSTP-organoids as a class (Figure 5B). APC mutation was a key gene for forming an adenoma. The adenoma still maintained the benign state after introducing SMAD4 mutation. KRAS mutation made the adenoma canceration by dysregulating the activities of many functions, implying KRAS mutation played a key role during transformation from adenoma to CRC.

Among the 186 functions, 56 showed no significance of activity difference between any type organoid and CRCs. Twenty one functions also showed no significance between normal and CRC samples, indicating these functions may be essential functions for maintaining cell survival. However, the other 35 functions showed significant activity difference between normal and CRC samples, of which 16 functions were metabolism-related, implying the serious metabolic derangements have occurred from an adenoma. Meanwhile, we found that 27 functions showed significant activity difference between all of five types of organoids and CRCs, such as the PI3K signaling pathway, suggesting that additional key driver mutations were needed to transform the organoids to CRCs.

Prioritizing Gene Cascading Paths Contributing to the Model of Colorectal Cancer Derived From Engineered Organoids

The five driver genes were not sufficient to make organoids approximate the physiological state of CRCs with features of metastasis and invasion (Matano et al., 2015). Meanwhile, due to tumor heterogeneity of CRCs, the mutations of five driver genes could explain development mechanisms of a part of CRC patients. Additional gene cascading paths were needed to explain the pathogenesis of broad CRC populations.

Using random walk to propagate information flow from dysregulated functions, we identified potential subsequent key genes for five types of organoids. At FDR = 0.05, we predicted 34, 89, 56, 4 potential key genes for A-, AS-, AK-, and AKST-organoids, respectively (Figures S6A,B and Table S6). For A- and AS-organoids, both PIK3CA and KRAS were identified, and PIK3CA was the top one gene identified from AK- and AKST-organoids, suggesting our method was able to identify key genes (Figure S6C). We also found that different organoids needed some common and specific potential genes to compete CRC progression (Figures S6B,C).

Heterogeneity in genetic alterations across CRC populations indicated that different combinations of key genes contributed to the tumor progression through participating in similar functions. Prioritizing gene cascading paths for different organoids, which could perform analogical functions of five driver genes, could provide the interpretation of pathogenesis for broader CRC patients. Functional analysis showed the high functional coherence among the five driver genes. We calculated the function coherence among the potential genes and five known genes, and found that many potential key genes showed high functional coherence with the five known genes (Figures S7–S11). Thus, using the five driver genes as template, we prioritized cascading paths of key genes based on the function coherence to recapitulate the adenoma-carcinoma sequence model for different organoids (Figures 6A–E).

FIGURE 6

Figure 6. The potential gene cascading paths for five different organoids. Red node represents mutant genes in organoids, orange nodes for potential genes. (A) A-organoid. (B) AK-organoid. (C) AS-organoid. (D) AKST-organoid. (E) AKSTP-organoid.

For A-organoids, two paths of potential key genes were predicted: one contained APC, ERBB4, NRG1, KRAS, PIK3CA, and PIK3CG, and the other contained APC, ERBB4, LATS2, TIAM1, and DLC1 (Figure 6A). ERBB4, one of the ErbB receptor tyrosine kinases, showed the functional coherence of 0.56, 0.59, 0.63, and 0.57 with APC, KRAS, PIK3CA, and TP53, respectively, which also participated in cancer associated functions such as MAPK cascade, cell migration and cell proliferation. The colonic inflammation was limited by ErbB4 signaling through stimulating pro-inflammatory macrophage apoptosis (Schumacher et al., 2017). ERBB4 itself could not induce tumor transformation of mouse colonocytes, while under the condition of colonocytes with mutant Apc and Ras, ERBB4 enhanced the transformed phenotype both in vitro and in vivo (Williams et al., 2015). The increased co-expression of ErbB4-CYT-2 with KITENIN promoted the transition of colon adenoma to adenocarcinoma in tumor microenvironment of APC loss (Bae et al., 2016). NRG1, neuregulin 1, showed the functional coherence of 0.54, 0.58, 0.55, 0.58, and 0.51 with APC, KRAS, PIK3CA, SMAD4, and TP53, respectively. In the ERBB signaling pathway, NRG1 could participate in cell migration and invasion by activating ERBB4 and KRAS, and contribute to cell cycle and cell metabolism by activating ERBB4 and PIK3CA. NRG1 was methylated in tumors and the knockdown of NRG1 could increase net cell proliferation (Chua et al., 2009). Paracrine NRG1/HER3 signals promoted CRC cell progression, and was associated with poor prognosis in CRC (De Boeck et al., 2013). PI3KCG was a critical switch between immune stimulation and suppression during inflammation and tumor growth (Kaneda et al., 2016). The silencing of PIK3CG contributed to inhibit the PI3K-Akt/PKB signaling system which was responsible for the tumorigenesis and progression of colorectal cancers (Semba et al., 2002). Thus, ERBB4 and NRG3 may replace SMAD4 and TP53 to form a new combination, together with APC, KRAS and PIK3CA, to form an alternative path underlying CRCs.

For ASKT-organoids, PIK3CA was ranked first, together with APC, SMAD4, KRAS, and TP53, which restored the known the adenoma-carcinoma sequence model of CRC (Figure 6D). ASKTP-organoids were capable to form the tumors while showed weak invasive behavior. Additional key genes were needed to complete the progression of CRC. PKHD1 were the second potential key genes which showed function coherence of 0.47, 0.49, 0.48, 0.45, and 0.45 with APC, SMAD4, KRAS, TP53, and PIC3CA, respectively. The protein encoded by PKHD1 harbored the structural features with hepatocyte growth-factor receptor and plexins which involved in regulation of cell proliferation and cellular adhesion and repulsion (Onuchic et al., 2002). Inhibition of PKHD1 may control cell cycle via mTOR signaling pathway (Zheng et al., 2009), and induced cell apoptosis through PI3K and NF-κB pathways (Sun et al., 2011). We found that PKHD1 showed high frequency of mutations in the CRC populations (from 8.9 to 11.8%, Figure S12). Previous studies showed that PKHD1 was a candidate CRC gene by screening mutations in the consensus coding sequences profile, and was assigned to the function of cell adhesion with the first rank (Sjöblom et al., 2006). The germline mutations of PKHD1 played a protective role in colorectal cancer (Ward et al., 2011). Thus, introduction of PKHD1 mutations following the five driver genes may contribute to CRC invasion and metastasis.

Discussion

The adenoma-carcinoma sequence was recognized as the mechanism model of CRC, in which mutations of APC, KRAS, SMAD4, TP53, and PIK3CA could sequentially drive CRC transformation. The sequential introduction of CRC genes was used to model colorectal cancer. These studies gave a clue that it is possible to investigate the CRC dynamic progression using engineered organoids. We proposed an integrative strategy to characterize the dynamic progression of CRC and prioritize gene cascading paths for directing subsequent introductions of key genes.

Dynamic analysis of activities of biological functions showed biological gaps between organoids and CRC tissues. The number of dysregulated functions dropped sharply with the number of mutations of key genes increasing. These results were consistent with previous studies (Drost et al., 2015; Matano et al., 2015), suggesting that our method could capture biological dynamics and characterize the CRC progression. The AKST- and AKSTP- organoids approximated the true CRC with corresponding mutations. However, there were still many dysregulated functions associated with tumor metastasis, such as cytokine-cytokine receptor interaction, ECM-receptor interaction, and adherent junction. Meanwhile, some tumor microenvironment associated functions including antigen processing and presentation, leukocyte transendothelial migration and chemokine signaling pathway were also in these biological gaps. The identified dysregulated functions may provide an explaining that AKST- and AKSTP-organoids without features of migration and invasion may be due to lacking of tumor microenvironment supporting invasion and metastasis. Additional driver mutations of key genes were needed to further identify to control these functions.

Through screening the genetic alteration profiles of CRC populations, the co-occurrence frequency of five CRC genes was low. Although the adenoma-carcinoma sequence of CRC was recognized, it only explained molecular mechanism in a fraction of CRC populations with mutations of all five genes. The genetic alterations of CRC populations showed high heterogeneity, implicating that other key genes were required for drawing the mechanism of colon carcinogenesis for most of CRC populations. Our method not only could characterize biological gaps between different types of organoids and their corresponding CRC samples, but also be able to predict key genes which followed the introduced key mutation to further shrink biological gaps. The potential sequential genes were identified for different types of organoids, which participated in important functions and pathways. For example, for the AK-organoids, 56 subsequent genes were predicted. Using functional enrichment, many cancer-associated functions, such as MAPK cascade, Ras signaling pathway, PI3K-Akt signaling pathway, positive regulation of cell migration and positive regulation of cell proliferation, were identified (Table S7). With the accumulation of published studies about CRC organoids and multidimensional omics data of organoids (Fumagalli et al., 2017; Newey et al., 2019; Ooft et al., 2019), our method could be used to identify more extensive gene paths and construct the landscape of molecular pathogenesis for CRC cancer. Sequential introduction of the mutations in gene paths may provide a new avenue for understanding the dynamic progression of CRC.

In summary, we developed an integrative strategy to capture the dynamic progression of CRC and prioritize gene cascading paths for understanding the mechanisms of wide CRC patients. Our approach also can reveal the dynamic transformation mechanism of other cancer types. This will provide a more detailed interpretation for molecular mechanisms of cancer which could help for drug design and cancer therapy.

Data Availability Statement

Publicly available datasets were analyzed in this study. This data can be found here: GSE57965(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57965), TCGA(https://portal.gdc.cancer.gov/).

Author Contributions

XL and YX designed and guided this work and LW supervised this work. YP, CX, LX, and GL participated in data processing, program implementation, and paper writing. YZ, CD, YL, FY, and JS contributed to data collecting and organized the figures and tables. All authors provided critical advice for the final manuscript.

Funding

This work was supported in part by the National High Technology Research and Development Program of China [863 Program, Grant No. 2014AA021102], the National Program on Key Basic Research Project [973 Program, Grant No. 2014CB910504], the National Natural Science Foundation of China [Grant Nos. 61573122, 31601076], the China Postdoctoral Science Foundation (2016M601444), Wu lien-teh youth science fund project of Harbin medical university [Grant No. WLD-QN1407], Special funds for the construction of higher education in Heilongjiang Province [Grant No. UNPYSCT-2018068], the Heilongjiang Postdoctoral Foundation (LBH-Z16119).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

The authors acknowledged the contributions of the data used in this work by all the researchers to public database GEO, TCGA, cBioPortal, and MSigDB. All the research results based on the data are the sole responsibility of the authors.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fbioe.2020.00012/full#supplementary-material

References

Amar, D., Hait, T., Izraeli, S., and Shamir, R., et al. (2015). Integrated analysis of numerous heterogeneous gene expression profiles for detecting robust disease-specific biomarkers and proposing drug targets. Nucleic Acids Res. 43, 7779–7789. doi: 10.1093/nar/gkv810

PubMed Abstract | CrossRef Full Text | Google Scholar

Bae, J. A., Kho, D. H., Sun, E. G., Ko, Y. S., Yoon, S., Lee, K. H., et al. (2016). Elevated coexpression of KITENIN and the ErbB4 CYT-2 Isoform promotes the transition from colon adenoma to carcinoma following APC loss. Clin. Cancer Res. 22, 1284–1294. doi: 10.1158/1078-0432.CCR-15-0306

PubMed Abstract | CrossRef Full Text | Google Scholar

Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., et al. (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353–357. doi: 10.1038/nature04296

PubMed Abstract | CrossRef Full Text | Google Scholar

Brenner, H., Kloor, M., and Pox, C. P. (2014). Colorectal cancer. Lancet 383, 1490–1502. doi: 10.1016/S0140-6736(13)61649-9

PubMed Abstract | CrossRef Full Text | Google Scholar

Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., et al. (2012). The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404. doi: 10.1158/2159-8290.CD-12-0095

PubMed Abstract | CrossRef Full Text | Google Scholar

Chen, H. J., Wei, Z., Sun, J., Bhattacharya, A., Savage, D. J., Serda, R., et al. (2016). A recellularized human colon model identifies cancer driver genes. Nat. Biotechnol. 34, 845–851. doi: 10.1038/nbt.3586

PubMed Abstract | CrossRef Full Text | Google Scholar

Chua, Y. L., Ito, Y., Pole, J. C., Newman, S., Chin, S. F., Stein, R. C., et al. (2009). The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene. Oncogene 28, 4041–4052. doi: 10.1038/onc.2009.259

PubMed Abstract | CrossRef Full Text | Google Scholar

Cooks, T., Pateras, I. S., Tarcic, O., Solomon, H., Schetter, A. J., Wilder, S., et al. (2013). Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 23, 634–646. doi: 10.1016/j.ccr.2013.03.022

PubMed Abstract | CrossRef Full Text | Google Scholar

De Boeck, A., Pauwels, P., Hensen, K., Rummens, J. L., Westbroek, W., Hendrix, A., et al. (2013). Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling. Gut 62, 550–560. doi: 10.1136/gutjnl-2011-301393

PubMed Abstract | CrossRef Full Text | Google Scholar

Drier, Y., Sheffer, M., and Domany, E. (2013). Pathway-based personalized analysis of cancer. Proc. Natl. Acad. Sci. U.S.A. 110, 6388–6393. doi: 10.1073/pnas.1219651110

PubMed Abstract | CrossRef Full Text | Google Scholar

Drost, J., van Jaarsveld, R. H., Ponsioen, B., Zimberlin, C., van Boxtel, R., Buijs, A., et al. (2015). Sequential cancer mutations in cultured human intestinal stem cells. Nature 521, 43–47. doi: 10.1038/nature14415

PubMed Abstract | CrossRef Full Text | Google Scholar

Fearon, E. R., and Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis. Cell 61, 759–767. doi: 10.1016/0092-8674(90)90186-i

PubMed Abstract | CrossRef Full Text | Google Scholar

Fumagalli, A., Drost, J., Suijkerbuijk, S. J., van Boxtel, R., de Ligt, J., Offerhaus, G. J., et al. (2017). Genetic dissection of colorectal cancer progression by orthotopic transplantation of engineered cancer organoids. Proc. Natl. Acad. Sci. U.S.A. 114, E2357–E2364. doi: 10.1073/pnas.1701219114

PubMed Abstract | CrossRef Full Text | Google Scholar

Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., et al. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6:pl1. doi: 10.1126/scisignal.2004088

PubMed Abstract | CrossRef Full Text | Google Scholar

Gatza, M. L., Lucas, J. E., Barry, W. T., Kim, J. W., Wang, Q., Crawford, M. D., et al. (2010). A pathway-based classification of human breast cancer. Proc. Natl. Acad. Sci. U.S.A. 107, 6994–6999. doi: 10.1073/pnas.0912708107

PubMed Abstract | CrossRef Full Text | Google Scholar

Hänzelmann, S., Castelo, R., and Guinney, J. (2013). GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14:7. doi: 10.1186/1471-2105-14-7

PubMed Abstract | CrossRef Full Text | Google Scholar

Hao, Y., Samuels, Y., Li, Q., Krokowski, D., Guan, B. J., Wang, C., et al. (2016). Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. Nat. Commun. 7:11971. doi: 10.1038/ncomms11971

PubMed Abstract | CrossRef Full Text | Google Scholar

Heckl, D., Kowalczyk, M. S., Yudovich, D., Belizaire, R., Puram, R. V., McConkey, M. E., et al. (2014). Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat. Biotechnol. 32, 941–946. doi: 10.1038/nbt.2951

PubMed Abstract | CrossRef Full Text | Google Scholar

Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., et al. (2016). PI3Kγ is a molecular switch that controls immune suppression. Nature 539, 437–442. doi: 10.1038/nature19834

PubMed Abstract | CrossRef Full Text | Google Scholar

Kanehisa, M., and Goto, S. (2000). KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30. doi: 10.1093/nar/28.1.27

PubMed Abstract | CrossRef Full Text | Google Scholar

Keshava Prasad, T. S., Goel, R., Kandasamy, K., Keerthikumar, S., Kumar, S., Mathivanan, S., et al. (2009). Human protein reference database−2009 update. Nucleic Acids Res. 37, D767–D772. doi: 10.1093/nar/gkn892

PubMed Abstract | CrossRef Full Text | Google Scholar

Köhler, S., Bauer, S., Horn, D., and Robinson, P. N. (2008). Walking the interactome for prioritization of candidate disease genes. Am. J. Hum. Genet. 82, 949–958. doi: 10.1016/j.ajhg.2008.02.013

PubMed Abstract | CrossRef Full Text | Google Scholar

Lee, E., Chuang, H. Y., Kim, J. W., Ideker, T., and Lee, D. (2008). Inferring pathway activity toward precise disease classification. PLoS Comput. Biol. 4:e1000217. doi: 10.1371/journal.pcbi.1000217

PubMed Abstract | CrossRef Full Text | Google Scholar

Li, C., Li, X., Miao, Y., Wang, Q., Jiang, W., Xu, C., et al. (2009). SubpathwayMiner: a software package for flexible identification of pathways. Nucleic Acids Res. 37:e131. doi: 10.1093/nar/gkp667

PubMed Abstract | CrossRef Full Text | Google Scholar

Liberzon, A., Birger, C., Thorvaldsdottir, H., Ghandi, M., Mesirov, J. P., and Tamayo, P. (2015). The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425. doi: 10.1016/j.cels.2015.12.004

PubMed Abstract | CrossRef Full Text | Google Scholar

Matano, M., Date, S., Shimokawa, M., Takano, A., Fujii, M., Ohta, Y., et al. (2015). Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat. Med. 21, 256–262. doi: 10.1038/nm.3802

PubMed Abstract | CrossRef Full Text | Google Scholar

Morizane, R., Lam, A. Q., Freedman, B. S., Kishi, S., Valerius, M. T., and Bonventre, J. V. (2015). Nephron organoids derived from human pluripotent stem cells model kidney development and injury. Nat. Biotechnol. 33, 1193–1200. doi: 10.1038/nbt.3392

PubMed Abstract | CrossRef Full Text | Google Scholar

Nakayama, M., Sakai, E., Echizen, K., Yamada, Y., Oshima, H., Han, T. S., et al. (2017). Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation. Oncogene 36, 5885–5896. doi: 10.1038/onc.2017.194

PubMed Abstract | CrossRef Full Text | Google Scholar

Newey, A., Griffiths, B., Michaux, J., Pak, H. S., Stevenson, B. J., Woolston, A., et al. (2019). Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. J Immunother. Cancer 7:309. doi: 10.1186/s40425-019-0769-8

CrossRef Full Text | Google Scholar

Onuchic, L. F., Furu, L., Nagasawa, Y., Hou, X., Eggermann, T., Ren, Z., et al. (2002). PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats. Am. J. Hum. Genet. 70, 1305–1317. doi: 10.1086/340448

PubMed Abstract | CrossRef Full Text | Google Scholar

Onuma, K., Ochiai, M., Orihashi, K., Takahashi, M., Imai, T., Nakagama, H., et al. (2013). Genetic reconstitution of tumorigenesis in primary intestinal cells. Proc. Natl. Acad. Sci. U.S.A. 110, 11127–11132. doi: 10.1073/pnas.1221926110

PubMed Abstract | CrossRef Full Text | Google Scholar

Ooft, S. N., Weeber, F., Dijkstra, K. K., McLean, C. M., Kaing, S., van Werkhoven, E., et al. (2019). Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci. Transl. Med. 11:eaay2574. doi: 10.1126/scitranslmed.aay2574

PubMed Abstract | CrossRef Full Text | Google Scholar

O'Rourke, K. P., Loizou, E., Livshits, G., Schatoff, E. M., Baslan, T., Manchado, E., et al. (2017). Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer. Nat. Biotechnol. 35, 577–582. doi: 10.1038/nbt.3837

PubMed Abstract | CrossRef Full Text | Google Scholar

Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., et al. (2014). CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159, 440–455. doi: 10.1016/j.cell.2014.09.014

PubMed Abstract | CrossRef Full Text | Google Scholar

Powell, S. M., Zilz, N., Beazer-Barclay, Y., Bryan, T. M., Hamilton, S. R., Thibodeau, S. N., et al. (1992). APC mutations occur early during colorectal tumorigenesis. Nature 359, 235–237. doi: 10.1038/359235a0

PubMed Abstract | CrossRef Full Text | Google Scholar

Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., and Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308. doi: 10.1038/nprot.2013.143

PubMed Abstract | CrossRef Full Text | Google Scholar

Riemer, P., Rydenfelt, M., Marks, M., van Eunen, K., Thedieck, K., Herrmann, B. G., et al. (2017). Oncogenic β-catenin and PIK3CA instruct network states and cancer phenotypes in intestinal organoids. J. Cell Biol. 216, 1567–1577. doi: 10.1083/jcb.201610058

PubMed Abstract | CrossRef Full Text | Google Scholar

Roper, J., Tammela, T., Cetinbas, N. M., Akkad, A., Roghanian, A., Rickelt, S., et al. (2017). In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Nat. Biotechnol. 35, 569–576. doi: 10.1038/nbt.3836

CrossRef Full Text | Google Scholar

Rosenfeldt, M. T., O'Prey, J., Morton, J. P., Nixon, C., MacKay, G., Mrowinska, A., et al. (2013). p53 status determines the role of autophagy in pancreatic tumour development. Nature 504, 296–300. doi: 10.1038/nature12865

PubMed Abstract | CrossRef Full Text | Google Scholar

Sánchez-Rivera, F. J., Papagiannakopoulos, T., Romero, R., Tammela, T., Bauer, M. R., Bhutkar, A., et al. (2014). Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature 516, 428–431. doi: 10.1038/nature13906

PubMed Abstract | CrossRef Full Text | Google Scholar

Schumacher, M. A., Hedl, M., Abraham, C., Bernard, J. K., Lozano, P. R., Hsieh, J. J., et al. (2017). ErbB4 signaling stimulates pro-inflammatory macrophage apoptosis and limits colonic inflammation. Cell Death Dis. 8:e2622. doi: 10.1038/cddis.2017.42

PubMed Abstract | CrossRef Full Text | Google Scholar

Semba, S., Itoh, N., Ito, M., Youssef, E. M., Harada, M., Moriya, T., et al. (2002). Down-regulation of PIK3CG, a catalytic subunit of phosphatidylinositol 3-OH kinase, by CpG hypermethylation in human colorectal carcinoma. Clin. Cancer Res. 8, 3824–3831.

PubMed Abstract | Google Scholar

Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science 314, 268–274. doi: 10.1126/science.1133427

PubMed Abstract | CrossRef Full Text | Google Scholar

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545–15550. doi: 10.1073/pnas.0506580102

PubMed Abstract | CrossRef Full Text | Google Scholar

Sun, L., Wang, S., Hu, C., and Zhang, X. (2011). Down-regulation of PKHD1 induces cell apoptosis through PI3K and NF-κB pathways. Exp. Cell Res. 317, 932–940. doi: 10.1016/j.yexcr.2011.01.025

PubMed Abstract | CrossRef Full Text | Google Scholar

Takeda, H., Kataoka, S., Nakayama, M., Ali, M. A. E., Oshima, H., Yamamoto, D., et al. (2019). CRISPR-Cas9-mediated gene knockout in intestinal tumor organoids provides functional validation for colorectal cancer driver genes. Proc. Natl. Acad. Sci. U.S.A. 116, 15635–15644. doi: 10.1073/pnas.1904714116

PubMed Abstract | CrossRef Full Text | Google Scholar

Tang, J., Feng, Y., Kuick, R., Green, M., Green, M., Sakamoto, N., et al. (2019). Trp53 null and R270H mutant alleles have comparable effects in regulating invasion, metastasis, and gene expression in mouse colon tumorigenesis. Lab. Invest. 99, 1454–1469. doi: 10.1038/s41374-019-0269-y

PubMed Abstract | CrossRef Full Text | Google Scholar

van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., et al. (2015). Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933–945. doi: 10.1016/j.cell.2015.03.053

PubMed Abstract | CrossRef Full Text | Google Scholar

van Lidth de Jeude, J. F., Meijer, B. J., Wielenga, M. C. B., Spaan, C. N., Baan, B., Rosekrans, S. L., et al. (2017). Induction of endoplasmic reticulum stress by deletion of Grp78 depletes Apc mutant intestinal epithelial stem cells. Oncogene 36, 3397–3405. doi: 10.1038/onc.2016.326

PubMed Abstract | CrossRef Full Text | Google Scholar

Vogelstein, B., and Kinzler, K. W. (2004). Cancer genes and the pathways they control. Nat. Med. 10, 789–799. doi: 10.1038/nm1087

PubMed Abstract | CrossRef Full Text | Google Scholar

Wang, J. Z., Du, Z., Payattakool, R., Yu, P. S., and Chen, C. F. (2007). A new method to measure the semantic similarity of GO terms. Bioinformatics 23, 1274–1281. doi: 10.1093/bioinformatics/btm087

PubMed Abstract | CrossRef Full Text | Google Scholar

Ward, C. J., Wu, Y., Johnson, R. A., Woollard, J. R., Bergstralh, E. J., Cicek, M. S., et al. (2011). Germline PKHD1 mutations are protective against colorectal cancer. Hum. Genet. 129, 345–349. doi: 10.1007/s00439-011-0950-8

PubMed Abstract | CrossRef Full Text | Google Scholar

Williams, C. S., Bernard, J. K., Demory Beckler, M., Almohazey, D., Washington, M. K., Smith, J. J., et al. (2015). ERBB4 is over-expressed in human colon cancer and enhances cellular transformation. Carcinogenesis 36, 710–718. doi: 10.1093/carcin/bgv049

PubMed Abstract | CrossRef Full Text | Google Scholar

Xue, W., Chen, S., Yin, H., Tammela, T., Papagiannakopoulos, T., Joshi, N. S., et al. (2014). CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 514, 380–384. doi: 10.1038/nature13589

PubMed Abstract | CrossRef Full Text | Google Scholar

Yang, X., Regan, K., Huang, Y., Zhang, Q., Li, J., Seiwert, T. Y., et al. (2012). Single sample expression-anchored mechanisms predict survival in head and neck cancer. PLoS Comput. Biol. 8:e1002350. doi: 10.1371/journal.pcbi.1002350

PubMed Abstract | CrossRef Full Text | Google Scholar

Zheng, R., Wang, L., Fan, J., and Zhou, Q. (2009). Inhibition of PKHD1 may cause S-phase entry via mTOR signaling pathway. Cell Biol. Int. 33, 926–933. doi: 10.1016/j.cellbi.2009.06.012

PubMed Abstract | CrossRef Full Text | Google Scholar